EPC 2024: Updates in Pulmonary Disease: Current, Relevant & Interactive

September 12, 2024 to September 15, 2024

The Eastern Pulmonary Conference (EPC) plans and organizes an annual CME meeting on clinical topics in Pulmonary Medicine.  With didactic lectures, panel discussions, and problem-based learning (PBL) case discussions, EPC blends the interactivity characteristic of a small regional conference with the relevant information that can improve the diagnostic accuracy and the effectiveness of treatments with practitioners who treat pulmonary diseases.  

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and the Eastern Pulmonary Conference (EPC). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 16 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 16 contact hours.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

At the conclusion of this activity learners should be able to…

•    Describe the pathophysiology of asthma exacerbations attributable to respiratory infections. 
•    Discuss the differential diagnosis and management of pulmonary hypertension and CTEPH.
•    Explain the clinical presentations, treatments, and outcomes in adult and children with cystic fibrosis
•    Describe the clinical presentations, treatments, and outcomes in patients with NTM lung disease 
•    Discuss the role of cell-based and monoclonal therapeutic approaches in lung cancer
•    Utilize diagnostic tests and clinical history to diagnose hypersensitivity pneumonitis 
•    Discuss the use of augmented intelligence and machine learning in pulmonary medicine
•    Appropriately prescribe biologic therapy for asthma management
•    Implement the newest guidelines in the management of asthma and COPD. 
•    Conduct a shared decision-making conversation regarding treatment options for rescue therapy in asthma management.
•    Describe how phenotypes of COPD predict therapeutic responses.
•    Implement recent advances in managing acute respiratory failure in the ICU.
•    Discuss the role of immunobiology in the pathophysiology and treatment of lung diseases.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

NO CORPORATE SUPPORT WAS RECEIVED FOR THIS ACTIVITY.

Course summary
Available credit: 
  • 16.00 AMA PRA Category 1 Credit™
  • 16.00 Attendance
  • 16.00 CBRN
Course opens: 
09/12/2024
Course expires: 
12/31/2025
Event starts: 
09/12/2024 - 4:30pm CDT
Event ends: 
09/15/2024 - 9:30am CDT
Add to calendar: 
Rating: 
0

Eastern Pulmonary Conference Meeting Program    
September 12 - 15, 2024

Thursday, September 12
Moderator: Rey Panettieri, MD

3:30 – 4:00 pm PAH Update, Roger Alvarez, MD

4:00 – 4:30 pm IPF: Current and future management, David Zisman, MD

4:30 – 5:00 pm Navigating the waters of drug-induced pulmonary toxicity, Abigail Koch, MD

5:00 – 5:15 pm Panel Discussion: Q & A

5:15 – 5:45 pm CTEPH: Latest updates and therapies, Roger Alvarez, MD

5:45 – 6:15 Emerging perspectives in secondary immunodeficiency, Antoine Azar, MD

6:15 – 6:30 Panel Discussion: Q & A
 
Friday, September 13, 2024
Moderator: Russell Settipane, MD

7:45 – 8:15 am Monoclonal antibodies in asthma management, Rey Panettieri, MD

8:15 – 8:45 am The future is now: AI and machine learning in pulmonary medicine, Momen Wahidi, MD

8:45 – 8:55 am Panel Discussion: Q & A

8:55 – 10:00 am PBL: A 38 -year-old woman with asthma
Ray Davis, MD, Don Bukstein, MD, Rey Panettieri, MD, Russ Settipane, MD

10:00 – 10:45 am Coffee Break: Visit exhibits and posters 

10:45 – 11:15 am Airways disease and rescue approaches, Rey Panettieri, MD

11:15 – 11:55 am ARDS unfolded: New definitions and phenotypes, Neil MacIntyre, MD

11:55 – 12:25 pm Cystic fibrosis in the young and old, Jeffrey Hoag, MD

12:25 – 12:35 pm Panel Discussion: Q & A Moderator: Robert Settipane, MD 

1:30 – 2:15 pm Critical care in review, Michael Pinsky, MD

2:15 – 2:45 pm Mechanical ventilation: What’s new?, Neil MacIntyre, MD

2:45 – 3:00 pm Panel Discussion: Q & A
 
Saturday, September 14, 2024
Moderator: William Greisner, III, MD

7:45 – 8:15 am Asthma exacerbations: The infectious side, Monica Kraft, MD

8:15 – 8:45 am Cell-based and monoclonal therapeutic approaches in lung cancer, Charles Powell, MD

8:45 – 8:55 am Panel Discussion: Q & A

8:55 – 10:00 am PBL: A 45-year-old woman with frequent COPD exacerbations
Ray Davis, MD, Don Bukstein, MD, Rey Panettieri, MD, Russ Settipane, MD

10:00 – 10:45 am Coffee Break: Visit exhibits and posters 

10:45 – 11:45 am New COPD guidelines, Barry Make, MD

11:45 – 12:15 pm Monoclonal antibodies in COPD management, Nick Hanania, MD

12:15 – 12:25 pm Panel Discussion: Q & A Moderator: Robert Settipane, MD 

1:20 – 1:50 pm Sarcoidosis, Mehdi Mirsaeidi, MD

1:50 – 2:20 pm Gizmos and gadgets for airway clearance, Ashwin Basavaraj, MD

2:20 – 2:30 pm Panel Discussion: Q & A

Sunday, September 15, 2024
Moderator: Rey Panettieri, MD

8:15 – 8:45 pm Complications of bronchoscopy, Momen Wahidi, MD

8:45 – 9:15 pm OSA and gender, Carolyn D’Ambrosia, MD

9:15 – 9:45 pm Diagnosis and management of hypersensitivity pneumonitis, Amanda Wu, MD

9:45 – 10:15 pm NTM lung disease: Is the treatment worse than the disease?, Joseph Khabbaza, MD

10:15 – 10:30 pm Panel Discussion: Q & A

The Breakers
Palm Beach, FL
United States

All relevant financial relationships with ineligible companies have been mitigated.

Roger Alvarez, MD – Speaker 
Speaker – United Therapeutics

Antoine Azar, MD - Speaker
Advisor – Grifols, Takeda, ADMA, CSL; Speaker – Grifols, ADMA

Don Bukstein, MD – Speaker
Speaker – Sanofi, Regeneron

Ray Davis MD – Speaker 
Consultant – Regeneron, Sanofi, Grifols, Kalvista, AstraZeneca

William Greisner III, MD – Planner, Moderator
Independent Contractor – Allakos, AstraZeneca, Allergy Therapeutics, GSK

Nicola Hanania, MD – Speaker 
Speaker – Sanofi, Regeneron; Advisor – GSK, Sanofi, Regeneron, Genentech, AstraZeneca, Amgen; Consultant – GSK, Sanofi, Regeneron, Genentech, AstraZeneca, Amgen; Researcher – GSK, Sanofi, Genentech, AstraZeneca, Cheisi

Joseph Khabbaza, MD – Speaker
Speaker – Insmed, Regeneron, Sanofi, Tactile; Consultant – Insmed, Tactile 

Monica Kraft, MD – Speaker 
Speaker – Chiesi Pharmaceuticals, Sanofi, AstraZeneca, Regeneron; Advisor - Chiesi Pharmaceuticals, AstraZeneca; Consultant – Sanofi, Regeneron

Neil MacIntyre, MD – Speaker
Consultant – Inogen, Insprix

Barry Make, MD – Speaker 
Advisor – Regeneron, Verona, AstraZeneca

Rey Panettieri, MD – Planner, Speaker, Moderator
Speaker – AstraZeneca, Sanofi, Merck & Co; Consultant – AstraZeneca, Teva; Advisor – AstraZeneca, Genentech; Researcher – AstraZeneca, Teva, Medimmune, AgoMab, Janssen

Charles Powell, MD – Speaker 
Consultant – Daiichi Sankyo, AstraZeneca, BioNTech, Pfizer, Duality Biologics, Bristol Myers Squibb, Merus, Seagen; Researcher – Archetype Therapeutics

Russell Settipane, MD – Planner, Reviewer, Speaker, Moderator
Speaker – AbbVie, Amgen, AstraZeneca, BioCryst, Genentech, GlaxoSmithKline, Grifols, Pharming, Regeneron, Sanofi, Takeda; Advisor – AbbVie, Pfizer, AstraZeneca, BioCryst, Kalvista, Pharming, GlaxoSmithKline, DBV; Independent Contractor –BioCryst, Regeneron

Momen Wahidi, MD – Speaker
Consultant – Olympus, Cook Medical, Verathon, Pinnacle Biologics      

The following have no relevant financial relationships with ineligible companies to disclose.
Joseph Bellanti, MD – Planner
Ashwin Basavaraj, MD – Speaker 
William Corrao, MD – Planner
Carolyn D’Ambrosio, MD – Speaker 
Jeffery Hoag, MD – Speaker 
Abigail Koch, MD – Speaker 
Katelyn Loiselle, BSN, RN – Planner
Ginny Loiselle – Coordinator
Mehdi Mirsaeidi, MD – Speaker
Michael Pinsky, MD – Speaker 
Robert Settipane, MD – Planner, Moderator
Kelli Wilson – Planner
Amanda Wu, MD – Speaker 
David Zisman, MD – Speaker 

Available Credit

  • 16.00 AMA PRA Category 1 Credit™
  • 16.00 Attendance
  • 16.00 CBRN
Please login or create an account to take this course.